ALEMBIC PHARMACEUTICALS LIMITED

BSE: APLLTD533573ISIN INE901L01018

Healthcare
Pharmaceuticals
BSE 1000

BSE listing

Share price

₹845.70+19.40 (+2.35%)

as of 18 Sep 2026

52W high: ₹998.00
52W low: ₹635.30
Off 52W high: -15.26%
1M return: +3.49%
3M return: +11.03%
6M return: +24.91%
1Y return: -11.76%
20D avg volume: 26,364
50 DMA: ₹821.42
200 DMA: ₹785.69

Key ratios Consolidated

Market cap: ₹16,623 Cr
Current price: ₹845.70
52W high / low: ₹998.00 / ₹635.30
Face value: ₹2.00
P/E: 24.11
P/B: —
EPS (TTM): ₹35.08
Book value / share: —
ROE: —
ROCE: 12.80%
Operating margin: —
Net margin: —
Debt / equity: 0.24
Net debt: ₹1,164 Cr
Interest cover: 8.41
Dividend yield: 1.42%
Dividend / share (TTM): ₹12.00
Payout: 34.21%
Cash conversion cycle: 156.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,150	1,848	1,876	1,910	1,711	1,770	1,693	1,648	1,562	1,517	1,631	1,595
	14.93	25.50	15.50	6.91	6.50	14.19	9.50	16.75	2.10	3.60	2.89	10.15
	1,943	1,731	1,686	1,695	1,527	1,591	1,525	1,498	1,407	1,337	1,449	1,470
	517.30	404.24	448.73	463.14	431.27	426.20	446.91	393.13	405.93	337.38	317.58	413.87
	120.50	129.79	143.11	126.82	109.16	92.64	120.18	102.64	95.50	110.53	165.45	88.68
	473.94	438.91	432.71	437.54	422.77	393.59	397.52	391.47	379.77	401.85	349.28	346.99
	27.61	22.56	23.31	24.23	23.52	24.52	22.26	18.81	13.18	10.94	15.17	15.69
	97.71	88.58	80.12	76.07	73.77	68.99	70.05	70.51	69.04	69.48	69.45	67.56
	723.89	648.74	621.13	641.00	599.20	573.51	595.46	588.13	—	475.70	554.16	578.26
	221.47	142.28	205.57	222.30	190.55	192.61	177.43	166.69	156.71	183.24	184.63	135.15
	0.00	-24.76	-42.23	0.00	0.00	0.00	0.00	12.88	0.00	0.00	0.00	0.00
	221.47	117.52	163.34	222.30	190.55	192.61	177.43	179.56	156.71	183.24	184.63	135.15
	49.50	-82.91	29.55	40.00	36.47	35.31	40.09	27.27	22.49	4.64	4.12	1.92
	172.36	201.54	131.95	183.71	153.63	156.63	137.69	153.15	134.54	178.21	180.46	136.56
	8.80	10.31	6.76	9.40	7.85	7.98	7.01	7.79	6.85	9.07	9.18	6.95
Key metrics
	346.79	228.66	266.77	322.60	287.84	286.12	269.74	268.88	238.93	263.66	269.25	218.40
	16.10%	12.40%	14.20%	16.90%	16.80%	16.20%	15.90%	16.30%	15.30%	17.40%	16.50%	13.70%
	8.00%	10.90%	7.00%	9.60%	9.00%	8.90%	8.10%	9.30%	8.60%	11.70%	11.10%	8.60%
	—	2.30%	—	4.40%	—	4.10%	—	—	—	—	—	—
	25.70%	4.40%	10.80%	15.90%	9.50%	16.70%	3.80%	3.30%	—	—	—	—
	12.20%	28.70%	-4.20%	20.00%	14.20%	-12.10%	-23.70%	12.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	7,784	7,345	6,672	6,229	5,653	5,306	5,393	4,606	3,935	3,131
	62.84	54.41	42.55	28.31	2.74	50.46	10.02	4.94	9.38	7.03
	7,055	6,639	6,021	5,624	5,270	4,736	4,035	3,567	3,195	2,597
	1,833	1,747	1,672	1,403	1,250	1,129	1,185	979.05	850.04	725.75
	520.22	508.88	410.96	454.91	380.08	360.50	265.92	270.93	234.93	201.87
	1,783	1,732	1,562	1,446	1,169	1,133	1,051	906.44	746.69	622.81
	97.71	93.63	78.77	56.19	50.17	17.73	16.02	27.16	18.41	3.40
	342.48	318.55	278.58	272.67	275.43	286.78	183.47	157.32	115.23	—
	2,635	2,510	2,308	2,134	2,066	1,852	1,527	1,437	1,322	979.34
	791.62	760.69	693.43	632.80	385.50	620.11	1,368	1,043	749.32	541.27
	-66.99	-66.98	12.87	0.00	0.00	0.00	0.00	-43.65	0.00	0.00
	724.63	693.71	706.30	632.80	385.50	620.11	1,368	999.83	749.32	541.27
	36.14	23.12	125.16	16.01	12.60	104.46	253.31	199.18	156.75	120.35
	689.56	670.83	582.01	615.82	341.99	520.94	1,147	800.70	583.29	412.83
	35.27	34.33	29.68	31.33	17.40	27.76	60.81	43.97	31.00	—
Key metrics
	1,165	1,106	1,064	961.66	711.10	924.62	1,568	1,184	882.96	544.67
	14.96%	15.10%	15.90%	15.40%	12.60%	17.40%	29.10%	25.70%	22.40%	17.40%
	8.86%	9.10%	8.70%	9.90%	6.10%	9.80%	21.30%	17.40%	14.80%	13.20%
	—	12.80%	14.60%	—	—	—	—	—	—	—
	—	10.10%	7.10%	10.20%	6.50%	-1.60%	17.10%	17.10%	25.70%	—
	—	15.30%	-5.50%	80.10%	-34.40%	-54.60%	43.20%	37.30%	41.30%	—
	—	348.11	-475.65	—	—	—	—	—	—	—
	—	1.17	0.15	—	—	—	—	—	—	—
	—	0.24	0.23	—	—	—	—	—	—	—
	—	1,164	1,112	—	—	—	—	—	—	—
	—	156.2	153.7	—	—	—	—	—	—	—
Balance sheet
	—	8,763	7,773	—	—	—	—	—	—	—
	—	4,543	4,088	—	—	—	—	—	—	—
	—	196.37	83.48	—	—	—	—	—	—	—
	—	1,466	1,400	—	—	—	—	—	—	—
	—	2,511	2,288	—	—	—	—	—	—	—
	—	338.39	287.23	—	—	—	—	—	—	—
	—	2,844	2,524	—	—	—	—	—	—	—
	—	835.08	879.89	—	—	—	—	—	—	—
	—	2,594	2,412	—	—	—	—	—	—	—
	—	1,361	1,196	—	—	—	—	—	—	—
	—	1,239	1,196	—	—	—	—	—	—	—
	—	121.92	0.00	—	—	—	—	—	—	—
	—	5,669	5,190	—	—	—	—	—	—	—
Cash flow
	—	782.73	87.97	—	—	—	—	—	—	—
	—	-506.05	-568.41	—	—	—	—	—	—	—
	—	-163.79	443.71	—	—	—	—	—	—	—
	—	434.62	563.62	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,868	1,719	1,642	1,796	1,494	—	1,406	1,580	1,476	1,475	1,588	1,479
	14.04	25.88	10.73	11.49	7.79	—	15.46	16.06	3.15	7.22	3.30	8.95
	1,626	1,546	1,472	1,591	1,376	—	1,318	1,409	1,266	1,266	1,335	1,354
	517.30	404.24	448.73	463.14	431.27	—	446.91	393.13	405.93	337.38	317.58	413.87
	119.92	94.37	104.73	97.97	97.50	—	105.13	96.10	94.36	109.20	164.87	85.68
	416.46	407.02	401.36	408.12	396.40	—	369.18	367.61	356.51	354.92	327.11	326.41
	21.41	19.42	21.65	22.81	22.64	—	21.79	18.28	12.69	10.13	14.66	15.38
	82.54	82.31	79.67	75.64	73.37	—	69.69	70.12	68.68	69.11	69.08	67.18
	550.81	522.72	464.59	500.90	466.76	—	478.78	481.20	439.01	410.11	—	475.50
	255.90	198.22	181.01	216.35	125.52	—	103.81	187.15	213.20	216.16	256.70	133.84
	0.00	-24.76	-42.23	0.00	0.00	—	—	12.88	—	—	—	—
	255.90	173.46	138.78	216.35	125.52	—	103.81	200.02	213.20	216.16	256.70	133.84
	58.94	69.61	24.31	36.99	22.00	—	18.00	34.24	37.01	14.29	23.46	—
	196.96	243.07	114.47	179.36	103.52	—	85.81	165.78	176.19	201.87	233.24	133.84
	10.02	12.37	5.82	9.12	5.27	—	4.37	8.43	8.96	10.27	11.87	6.81
Key metrics
	359.85	275.19	240.10	314.80	221.53	—	195.29	288.42	294.57	295.40	340.44	216.40
	19.30%	16.00%	14.60%	17.50%	14.80%	—	13.90%	18.30%	20.00%	20.00%	21.40%	14.60%
	10.50%	14.10%	7.00%	10.00%	6.90%	—	6.10%	10.50%	11.90%	13.70%	14.70%	9.10%
	—	3.30%	—	4.40%	—	—	—	—	—	—	—	—
	25.00%	—	16.80%	13.70%	1.30%	—	-11.50%	6.90%	—	—	—	—
	90.30%	—	33.40%	8.20%	-41.20%	—	-63.20%	23.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	7,025	6,651	6,033	5,874	5,149	4,997	5,051	4,133	3,660	2,945
	62.14	55.90	47.88	31.32	3.54	49.98	9.73	134.75	6.42	6.67
	6,236	5,986	5,485	5,201	4,807	4,138	3,645	3,091	2,902	2,417
	1,833	1,747	1,672	1,403	1,250	1,112	1,176	978.13	850.05	725.75
	416.99	394.57	385.14	449.70	337.21	353.35	279.33	244.26	230.45	203.16
	1,633	1,613	1,467	1,336	1,095	1,028	948.27	806.37	684.45	582.72
	85.29	86.51	76.47	54.47	49.00	16.67	12.77	25.19	14.87	2.22
	320.16	311.00	277.08	271.13	272.95	179.31	152.60	135.67	105.59	101.76
	2,039	1,955	1,876	1,739	1,730	1,430	1,233	1,077	1,097	837.26
	851.48	721.10	595.72	704.23	345.93	908.45	1,417	1,177	764.63	535.24
	-66.99	-66.99	12.87	—	—	—	—	-10.00	—	—
	784.49	654.11	608.59	704.23	345.93	908.45	1,417	1,167	764.63	535.24
	189.85	13.69	105.47	37.75	0.80	114.45	241.20	197.39	153.42	113.23
	733.86	640.42	503.12	666.48	346.73	794.00	1,175	969.40	611.21	422.01
	37.33	32.58	25.60	33.91	17.64	40.39	60.67	51.42	32.42	—
Key metrics
	1,190	1,052	962.14	1,030	667.88	1,104	1,582	1,328	885.09	639.22
	16.94%	15.80%	15.90%	17.50%	13.00%	22.10%	31.30%	32.10%	24.20%	21.70%
	10.45%	9.60%	8.30%	11.30%	6.70%	15.90%	23.30%	23.50%	16.70%	14.30%
	—	12.80%	12.80%	—	—	—	—	—	—	—
	—	10.30%	2.70%	14.10%	3.10%	-1.10%	22.20%	12.90%	24.30%	—
	—	27.30%	-24.50%	92.20%	-56.30%	-32.40%	21.20%	58.60%	44.80%	—
	—	377.49	-336.45	—	—	—	—	—	—	—
	—	1.26	0.45	—	—	—	—	—	—	—
	—	0.20	0.22	—	—	—	—	—	—	—
	—	1,127	1,128	—	—	—	—	—	—	—
	—	164.1	165.4	—	—	—	—	—	—	—
Balance sheet
	—	8,151	7,556	—	—	—	—	—	—	—
	—	4,001	3,766	—	—	—	—	—	—	—
	—	22.67	14.23	—	—	—	—	—	—	—
	—	1,604	1,481	—	—	—	—	—	—	—
	—	2,048	1,976	—	—	—	—	—	—	—
	—	284.10	255.78	—	—	—	—	—	—	—
	—	2,828	2,513	—	—	—	—	—	—	—
	—	660.70	724.57	—	—	—	—	—	—	—
	—	2,356	2,200	—	—	—	—	—	—	—
	—	1,149	1,142	—	—	—	—	—	—	—
	—	1,149	1,142	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	5,615	5,195	—	—	—	—	—	—	—
Cash flow
	—	809.46	226.57	—	—	—	—	—	—	—
	—	-483.43	-636.08	—	—	—	—	—	—	—
	—	-317.59	403.61	—	—	—	—	—	—	—
	—	431.97	563.02	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +8.91%
Sales CAGR 5Y: +5.66%
Sales CAGR 10Y: —
Profit CAGR 3Y: +22.69%
Profit CAGR 5Y: -11.44%
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: +9.12%
Sales CAGR 5Y: +6.37%
Sales CAGR 10Y: —
Profit CAGR 3Y: +25.18%
Profit CAGR 5Y: -10.16%
Profit CAGR 10Y: —
Sales YoY (TTM): +14.12%
Profit YoY (TTM): +14.72%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 69.88%

Holder	Type	Holding	Previous	Change
Nirayu Private Limited	Promoter Group	35.78%	—	—
Alembic Limited	Promoter	28.54%	—	—
Life Insurance Corporation Of India	Public	4.32%	—	—
Dsp Small Cap Fund	Public	3.86%	—	—
Chirayu Ramanbhai Amin	Promoter	2.13%	—	—
Kotak Small Cap Fund	Public	1.74%	—	—
Malika Chirayu Amin	Promoter Group	1.53%	—	—
Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund	Public	1.38%	—	—
Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund	Public	1.15%	—	—
Shaunak Chirayu Amin	Promoter	0.51%	—	—
Pranav Chirayu Amin	Promoter	0.51%	—	—
Udit Chirayu Amin	Promoter Group	0.51%	—	—
Chirayu Ramanbhai Amin HUF	Promoter Group	0.11%	—	—
Gallup Trust (Pranav Chirayu Amin)	Promoter Group	0.05%	—	—
Inaaya Shaunak Amin	Promoter Group	0.04%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Please find enclosed Intimation of One to One Investor Meet.18 Sep 2026 · Company Update / Analyst / Investor Meet
Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.16 Sep 2026 · Company Update / General
Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited''s Bioequivalence Facility in Vadodara, Gujarat.11 Sep 2026 · Company Update / General
Please find enclosed herewith the Intimation regarding Incorporation of a wholly owned subsidiary company of the Company.7 Sep 2026 · Company Update / General
Please find attached.27 Aug 2026 · Company Update / Analyst / Investor Meet
Please find attached.27 Aug 2026 · Company Update / Analyst / Investor Meet
Please find attached.25 Aug 2026 · Company Update / Newspaper Publication
Intimation regarding Appointment of Company Secretary of the Company.20 Aug 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
Please find attached.11 Aug 2026 · Company Update / Newspaper Publication
Please find attached.10 Aug 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Please find attached herewith the Transcript of Post Result Conference Call held on 4th August, 2026.10 Aug 2026 · Company Update / Earnings Call Transcript
Please find attached herewith the Scrutinizer Report and Voting Results of the AGM held on 5th August, 2026.6 Aug 2026 · AGM/EGM / AGM
Please find attached Proceedings of AGM held on 5th August, 2026.5 Aug 2026 · AGM/EGM / AGM
Please find attached herewith the Newspaper Advertisement.5 Aug 2026 · Company Update / Newspaper Publication
Please find attached audio recording of investor call.4 Aug 2026 · Company Update / Analyst / Investor Meet
Please find attached Revised Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.4 Aug 2026 · Company Update / Press Release / Media Release (Revised)
Please find attached Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.4 Aug 2026 · Company Update / Press Release / Media Release
Please find attached Investor Presentation.4 Aug 2026 · Company Update / Investor Presentation
Please find attached Unaudited Financial Results for the Quarter ended 30th June, 2026.4 Aug 2026 · Result / Financial Results
Please find enclosed herewith Outcome of Board Meeting.4 Aug 2026 · Board Meeting / Outcome of Board Meeting
Alembic Pharmaceuticals Limited receives USFDA Final approval for Prucalopride Tablets, 1 mg and 2 mg.28 Jul 2026 · Company Update / Press Release / Media Release
Please find attached herewith Intimation for Investors Call Scheduled to be held on 4th August, 2026.27 Jul 2026 · Company Update / Analyst / Investor Meet
Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve Unaudited Financial ....24 Jul 2026 · Board Meeting / Board Meeting
Alembic Pharmaceuticals Limited''s Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets 100 mg and 150 mg18 Jul 2026 · Company Update / Press Release / Media Release
Please find enclosed.13 Jul 2026 · Company Update / General
Please find enclosed herewith the copy of the Newspaper Publication published on 11th July, 2026.11 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed.10 Jul 2026 · Company Update / General
Please find enclosed herewith the intimation of Record Date for payment of Dividend on Equity Shares for the Financial Year ended 31st March, 2026.10 Jul 2026 · Corp. Action / Record Date
Please find enclosed herewith a copy of the Business Responsibility and Sustainability Report of the Company including Reasonable Assurance Report for the Financial Year ended 31st March, 2026.10 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed herewith a copy of Annual Report of the Company for the Financial Year ended 31st March, 2026.10 Jul 2026 · Others / Reg. 34 (1) Annual Report
Please find enclosed herewith a copy of the Notice of the 16th Annual General Meeting of the Company scheduled to be held on Wednesday, 5th August, 2026 at 4:00 p.m. IST.10 Jul 2026 · AGM/EGM / AGM
Please find enclosed Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th June, 2026.8 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed.7 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the Intimation of Re-affirmation of Credit Rating.1 Jul 2026 · Company Update / Credit Rating
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%.26 Jun 2026 · Company Update / Press Release / Media Release
Intimation of Closure of Trading Window.26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed.26 Jun 2026 · Company Update / Newspaper Publication
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6mg/mL.26 Jun 2026 · Company Update / Press Release / Media Release
Please find enclosed herewith Intimation of One of One Meet.19 Jun 2026 · Company Update / Analyst / Investor Meet
Please find enclosed herewith Intimation of One on One Meet.19 Jun 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 12.0000	29 Jul 2026	29 Jul 2026	—
Final Dividend - Rs. - 11.0000	29 Jul 2025	29 Jul 2025	—
Final Dividend - Rs. - 11.0000	15 Jul 2024	15 Jul 2024	—

Board meetings

4 Aug 2026 Board Meeting - Financial Results